Niemann-Pick type C disease (NPC) is a rare inherited neurodegenerative disorder characterized by an accumulation of intracellular cholesterol within late endosomes and lysosomes due to NPC1 or NPC2 dysfunction. In this work, we tested the hypothesis that retromer impairment may be involved in the pathogenesis of NPC and may contribute to increased amyloidogenic processing of APP and enhanced BACE1-mediated proteolysis observed in NPC disease. Using -null cells, primary mouse NPC1-deficient neurons and NPC1-deficient mice (BALB/cNctr-), we show that retromer function is impaired in NPC. This is manifested by altered transport of the retromer core components Vps26, Vps35 and/or retromer receptor sorLA and by retromer accumulation in neuronal processes, such as within axonal swellings. Changes in retromer distribution in NPC1 mouse brains were observed already at the presymptomatic stage (at 4-weeks of age), indicating that the retromer defect occurs early in the course of NPC disease and may contribute to downstream pathological processes. Furthermore, we show that cholesterol depletion in -null cells and in NPC1 mouse brains reverts retromer dysfunction, suggesting that retromer impairment in NPC is mechanistically dependent on cholesterol accumulation. Thus, we characterized retromer dysfunction in NPC and propose that the rescue of retromer impairment may represent a novel therapeutic approach against NPC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705785PMC
http://dx.doi.org/10.3390/ijms222413256DOI Listing

Publication Analysis

Top Keywords

retromer impairment
12
retromer
11
retromer function
8
niemann-pick type
8
type disease
8
intracellular cholesterol
8
cholesterol accumulation
8
npc
8
npc disease
8
-null cells
8

Similar Publications

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Amsterdam UMC location VUmc, Amsterdam, Noord-holland, Netherlands.

Background: SORL1 encodes the retromer-associated receptor SORLA that functions in endosomal recycling. Rare variants in SORL1 have been associated with Alzheimer's disease (AD) and rare pathogenic variants are estimated to occur in up to 2.75% of early onset AD patients and in 1.

View Article and Find Full Text PDF

Targeting VPS18 hampers retromer trafficking of PD-L1 and augments immunotherapy.

Sci Adv

October 2024

Key Laboratory of Natural Products & Chemical Biology of Ministry of Education, Institute of Medical Sciences, The Second Hospital of Shandong University, Jinan, China.

Article Synopsis
  • Immune checkpoint inhibitors that target PD-1 and PD-L1 show great potential in cancer treatment, but many patients exhibit limited responses due to insufficient understanding of how PD-L1 is regulated.
  • The study reveals that VPS11 and VPS18 proteins play a crucial role in regulating PD-L1 by affecting its stability and recycling in cells, which impacts the effectiveness of immune therapies.
  • The research suggests that using a drug called RDN, which inhibits VPS18, may improve cancer treatment outcomes when combined with existing therapies, especially in aggressive tumors, offering a new strategy to boost immune response against cancer.
View Article and Find Full Text PDF

Background: Apolipoprotein E (APOE) genotypes have been suggested to influence cognitive impairment and clinical onset in presenilin-1 (PSEN1) E280A carriers for autosomal dominant Alzheimer's disease (ADAD). Less is known about their impact on the trajectory of biomarker changes. Neurofilament light chain (NfL), a marker of neurodegeneration, begins to accumulate in plasma about 20 years prior to the clinical onset of ADAD.

View Article and Find Full Text PDF

The Neuronal alpha-Synuclein Disease (NSD) biological definition and Integrated Staging System (NSD-ISS) provide a research framework to identify individuals with Lewy body pathology and stage them based on underlying biology and increasing degree of functional impairment. Utilizing data from the PPMI, PASADENA, and SPARK studies, we developed and applied biologic and clinical data-informed definitions for the NSD-ISS across the disease continuum. Individuals enrolled as Parkinson's disease, Prodromal, or Healthy Controls were defined and staged based on biological, clinical, and functional anchors at baseline.

View Article and Find Full Text PDF
Article Synopsis
  • The Neuronal alpha-Synuclein Disease (NSD) and its Integrated Staging System (NSD-ISS) aim to identify and classify individuals with Lewy body pathology according to biological and functional factors.
  • Data from multiple studies reveal that a significant percentage of participants with Parkinson’s disease (PD) were classified as S+ (consistent with NSD), indicating a strong link between biological markers and disease staging.
  • Findings suggest that the baseline stage of individuals influences the timeline for progression to significant clinical outcomes, highlighting the need for further validation of the staging anchors in longer-term studies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!